New Releases from NCBI BookshelfMomelotinib (Ojjaara): Indication: For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia: Reimbursement Recommendation [Internet].​Momelotinib (Ojjaara): Indication: For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia: Reimbursement Recommendation [Internet].